Clinical Trial Update: A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone [Phase 3]

View source ↗

Summary

A Phase 3 study comparing erlotinib plus SU011248 versus erlotinib alone in patients with non-small cell lung cancer; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• SU011248

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2011-08-02